Tonix Pharmaceuticals (NASDAQ:TNXP) Coverage Initiated by Analysts at StockNews.com

StockNews.com assumed coverage on shares of Tonix Pharmaceuticals (NASDAQ:TNXP) in a research note issued to investors on Tuesday. The brokerage issued a sell rating on the stock.

Separately, Alliance Global Partners boosted their target price on Tonix Pharmaceuticals from $6.00 to $11.00 and gave the stock a “buy” rating in a research note on Monday, July 22nd.

Tonix Pharmaceuticals Price Performance

Shares of NASDAQ:TNXP opened at $0.14 on Tuesday. The firm’s 50-day moving average is $0.16 and its two-hundred day moving average is $1.67. The company has a current ratio of 1.15, a quick ratio of 0.72 and a debt-to-equity ratio of 0.13. Tonix Pharmaceuticals has a 1 year low of $0.12 and a 1 year high of $22.14.

Tonix Pharmaceuticals (NASDAQ:TNXP) last released its earnings results on Friday, August 16th. The company reported ($19.28) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($9.91) by ($9.37). The business had revenue of $2.21 million for the quarter, compared to analyst estimates of $3.50 million. Tonix Pharmaceuticals had a negative return on equity of 158.27% and a negative net margin of 1,196.11%. Analysts anticipate that Tonix Pharmaceuticals will post -18 EPS for the current year.

Institutional Investors Weigh In On Tonix Pharmaceuticals

A hedge fund recently raised its stake in Tonix Pharmaceuticals stock. Acadian Asset Management LLC raised its holdings in Tonix Pharmaceuticals Holding Corp. (NASDAQ:TNXP) by 260.6% during the first quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 335,373 shares of the company’s stock after buying an additional 242,358 shares during the period. Acadian Asset Management LLC owned about 0.40% of Tonix Pharmaceuticals worth $61,000 as of its most recent SEC filing. 82.26% of the stock is currently owned by institutional investors and hedge funds.

Tonix Pharmaceuticals Company Profile

Tonix Pharmaceuticals Holding Corp., a biopharmaceutical company, focuses on developing, discovering, commercializing, and licensing therapeutics to treat and prevent human disease and alleviate suffering. It markets Zembrace SymTouch and Tosymra for the treatment of acute migraine with or without aura in adults.